免疫检查点抑制剂免疫相关不良事件的肿瘤类型与药物类别特异性模式:系统综述
该系统综述检索了2003年至2015年11月的前瞻性单药免疫检查点抑制剂试验,共纳入48项试验、6938例患者。结果显示,CTLA-4单抗相比PD-1单抗的3/4级免疫相关不良事件更常见(31% vs 10%),且两者不良事件谱不同。PD-1单抗试验中黑色素瘤患者胃肠道和皮肤不良事件频率更高,肺炎频率更低。
要点
- CTLA-4单抗的3/4级免疫相关不良事件发生率为31%,PD-1单抗为10%。
- CTLA-4单抗更常见结肠炎、垂体炎和皮疹;PD-1单抗更常见肺炎、甲状腺功能减退、关节痛和白癜风。
- PD-1单抗试验中黑色素瘤患者胃肠道和皮肤不良事件频率高于非小细胞肺癌和肾细胞癌,肺炎频率更低。
核心结论
- CTLA-4和PD-1单抗具有不同的免疫相关不良事件谱。
- 不同的免疫微环境可能驱动组织学特异性的免疫相关不良事件模式。
- 随着免疫检查点抑制剂试验数据的积累,可能识别出其他肿瘤依赖性的免疫相关不良事件谱。
研究设计与样本
- 系统综述,检索Medline、EMBASE和COCHRANE数据库,纳入2003年至2015年11月的前瞻性单药免疫检查点抑制剂试验,由两名评审员独立选择文献并提取数据。
- 共纳入48项试验、6938例患者,包括26项CTLA-4试验、17项PD-1试验、2项PD-L1试验,以及3项同时测试CTLA-4和PD-1的研究。
- 使用比值比(OR)、χ2检验和多变量回归模型分析效应量和关联性。
主要发现
- CTLA-4单抗的3/4级免疫相关不良事件发生率为31%,PD-1单抗为10%。
- CTLA-4单抗相比PD-1单抗,所有级别结肠炎(OR 8.7,95% CI 5.8-12.9)、垂体炎(OR 6.5,95% CI 3.0-14.3)和皮疹(OR 2.0,95% CI 1.8-2.3)更频繁。
- PD-1单抗相比CTLA-4单抗,肺炎(OR 6.4,95% CI 3.2-12.7)、甲状腺功能减退(OR 4.3,95% CI 2.9-6.3)、关节痛(OR 3.5,95% CI 2.6-4.8)和白癜风(OR 3.5,95% CI 2.3-5.3)更常见。
- 在PD-1单抗试验中,黑色素瘤(n=2048)、非小细胞肺癌(n=1030)和肾细胞癌(n=573)三种研究最多的肿瘤类型比较显示,黑色素瘤患者胃肠道和皮肤免疫相关不良事件频率更高,肺炎频率更低。
关键数值与推荐
- CTLA-4单抗3/4级免疫相关不良事件发生率31%,PD-1单抗10%。
- CTLA-4单抗相比PD-1单抗:结肠炎OR 8.7(95% CI 5.8-12.9),垂体炎OR 6.5(95% CI 3.0-14.3),皮疹OR 2.0(95% CI 1.8-2.3)。
- PD-1单抗相比CTLA-4单抗:肺炎OR 6.4(95% CI 3.2-12.7),甲状腺功能减退OR 4.3(95% CI 2.9-6.3),关节痛OR 3.5(95% CI 2.6-4.8),白癜风OR 3.5(95% CI 2.3-5.3)。
- PD-1单抗试验中各肿瘤类型样本量:黑色素瘤n=2048,非小细胞肺癌n=1030,肾细胞癌n=573。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune checkpoint inhibitor (ICI) monoclonal antibodies (mAbs) targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1) or its ligand (PD-L1) produce unique toxicity profiles. The objective of this review was to identify patterns and incidence of immune-related adverse events (irAE) based on tumour type and ICI class. METHODS: Medline, EMBASE and COCHRANE databases were searched to identify prospective monotherapy trials of ICIs from 2003 to November 2015. Paired reviewers selected studies for inclusion and extracted data. Odds ratio (OR), χ2 tests and multivariable regression models were used to analyse for effect size and associations. RESULTS: We identified 48 trials (6938 patients), including 26 CTLA-4, 17 PD-1, 2 PD-L1 trials, and 3 studies tested both CTLA-4 and PD-1. Grade 3/4 irAE were more common with CTLA-4 mAbs compared with PD-1 (31% versus 10%). All grades colitis (OR 8.7, 95% CI 5.8-12.9), hypophysitis (OR 6.5, 95% CI 3.0-14.3) and rash (OR 2.0, 95% CI 1.8-2.3) were more frequent with CTLA-4 mAbs; whereas pneumonitis (OR 6.4, 95% CI 3.2-12.7), hypothyroidism (OR 4.3, 95% CI 2.9-6.3), arthralgia (OR 3.5, 95% CI 2.6-4.8) and vitiligo (OR 3.5, 95% CI 2.3-5.3) were more common with PD-1 mAbs. Comparison of irAE from the three most studied tumour types in PD-1 mAbs trials [melanoma (n = 2048), non-small-cell lung cancer (n = 1030) and renal cell carcinoma (n = 573)] showed melanoma patients had a higher frequency of gastrointestinal and skin irAE and lower frequency of pneumonitis. DISCUSSION: CTLA-4 and PD-1 mAbs have distinct irAE profiles. Different immune microenvironments may drive histology-specific irAE patterns. Other tumour-dependent irAE profiles may be identified as data emerge from ICI trials.
引用
- Khoja L, Day D, Wei-Wu Chen T, et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017. PMID: 28945858. doi:10.1093/annonc/mdx286
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。